Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β
H Hegen, M Auer, F Deisenhammer - Expert opinion on drug …, 2015 - Taylor & Francis
Introduction: Interferon-β (IFNβ) is well established as a disease-modifying treatment for
patients with multiple sclerosis. Several preparations of the biopharmaceutical are available …
patients with multiple sclerosis. Several preparations of the biopharmaceutical are available …
The role of interferon beta in neurological diseases and its potential therapeutic relevance
M Farhangian, F Azarafrouz, N Valian… - European Journal of …, 2024 - Elsevier
Interferon beta (IFNβ) is a member of the type-1 interferon family and has various
immunomodulatory functions in neuropathological conditions. Although the level of IFNβ is …
immunomodulatory functions in neuropathological conditions. Although the level of IFNβ is …
Interferon-alpha,-beta and-gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma …
It has been hypothesized that interferon (IFN) alpha and beta cause autoimmune thyroid
dysfunctions by changing the Th1/Th2 balance, but the mechanisms involved are not yet …
dysfunctions by changing the Th1/Th2 balance, but the mechanisms involved are not yet …
[HTML][HTML] Interferon-α,-β and-γ induce CXCL11 secretion in human thyrocytes: modulation by peroxisome proliferator-activated receptor γ agonists
A Antonelli, SM Ferrari, C Mancusi, V Mazzi, C Pupilli… - Immunobiology, 2013 - Elsevier
It has been previously shown IFN-α,-β,-γ and TNF-α (synergically with IFNs) dose-
dependently induce the release of CXCL9 and CXCL10 chemokines by thyroid follicular …
dependently induce the release of CXCL9 and CXCL10 chemokines by thyroid follicular …
[图书][B] Application of solution protein chemistry to biotechnology
RL Lundblad - 2009 - taylorfrancis.com
Reflecting the versatility of the author's science and the depth of his experience, Application
of Solution Protein Chemistry to Biotechnology explores key contributions that protein …
of Solution Protein Chemistry to Biotechnology explores key contributions that protein …
A randomized pharmacokinetic-pharmacodynamic evaluation of the potential biosimilar interferon beta-1a product, CinnoVex®
M Scheinin, Z Lovró, IH Maadik… - Expert Opinion on …, 2022 - Taylor & Francis
Background The objective of the trial was to evaluate the bioequivalence of the interferon
beta-1a (IFN beta-1a) biosimilar product candidate CinnoVex® with the reference product …
beta-1a (IFN beta-1a) biosimilar product candidate CinnoVex® with the reference product …
Pharmacokinetics and pharmacodynamics of interferon beta 1a in Cebus apella
M Lahoz, MA Kauffman, J Carfagnini… - Journal of Medical …, 2009 - Wiley Online Library
Background Recombinant human interferon (hIFNβ) is indicated for the treatment of multiple
sclerosis. Its effect presents species restriction, thus lacking biological activity on most …
sclerosis. Its effect presents species restriction, thus lacking biological activity on most …